NGS Oncology Assays

AVENIO NGS Oncology Assay kits provide researchers a versatile solution for tumor tissue and ctDNA analysis with an integrated end-to-end research workflow. With accurate and reliable analysis of ultra low ctDNA detection as well as formalin-fixed paraffin-embedded (FFPE) tissue samples, AVENIO NGS Oncology Assays offer laboratories ​​in-house tumor profiling, comprehensive genomic profiling (CGP), and surveillance & monitoring.¹ Each kit includes reagents for DNA extraction, sample input QC (for tissue), library preparation, target enrichment, robust bioinformatics, secondary analysis and reporting (variant calls).

• Flexibility to switch between tissue and plasma to support a variety of research applications, from targeted and expanded profiling to surveillance & monitoring*
• Matched tissue and ctDNA panels (same genes, gene regions and hybrid-capture workflow) for true concordance*
• All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow¹
• A streamlined, end-to-end research workflow from extraction to analysis and reporting in 5 days
• An integrated solution that includes reagents, intuitive analysis and reporting to facilitate in-house adoption of high performance NGS oncology research
• A Comprehensive Genomic Profiling (CGP) Kit with a 335-gene panel aligned with the FoundationOne® CDx panel design that enables detection of four classes of genomic variants and genomic signatures such as - Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), genomic Loss of Heterozygosity (gLOH) and newly added Homologous Recombination Deficiency signature (HRDsig).^2,3

AVENIO kits contain gene panels with biomarkers relevant to clinical cancer research over the course of disease evolution.